Physician profile
Bruce L Hughes
NPI 1285748004
$1,828,076.54
in general payments reported to CMS, 2019-2025
27 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441K · 2020: $177K · 2021: $200K · 2022: $323K · 2023: $266K · 2024: $257K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $504K · Consulting Fee: $94K · Travel and Lodging: $67K · Food and Beverage: $19K · Honoraria: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $504,174.50 |
| Consulting Fee | $94,176.91 |
| Travel and Lodging | $66,509.21 |
| Food and Beverage | $19,215.54 |
| Honoraria | $3,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $470,683.06 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $373,297.13 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| E.R. Squibb & Sons, L.L.C. | $199,837.76 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $187,029.43 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $125,881.85 | 2019-2025 | Zeposia |
| Tg Therapeutics, INC. | $102,815.36 | 2022-2025 | Briumvi |
| Janssen Pharmaceuticals, INC | $98,594.90 | 2021-2023 | Ponvory |
| Genzyme Corporation | $96,585.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $67,794.19 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $31,083.47 | 2019-2024 | Soliris |
| Amgen INC. | $27,054.96 | 2019-2025 | Uplizna |
| Ares Trading Sa | $22,531.30 | 2024 | |
| Vanda Pharmaceuticals INC. | $16,514.99 | 2024-2025 | Ponvory |
| Horizon Therapeutics Plc | $3,605.31 | 2023 | Uplizna |
| Genentech, INC. | $2,698.00 | 2020-2025 | Ocrevus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,620.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $106.09 | 2019 | |
| Sk Life Science, INC. | $97.68 | 2022 | |
| Abbvie INC. | $72.85 | 2022-2024 | |
| Pfizer INC. | $40.52 | 2024 | |
| Mallinckrodt Enterprises LLC | $31.47 | 2019 | |
| Lilly USA, LLC | $26.78 | 2019-2025 | Kisunla |
| Sunovion Pharmaceuticals INC. | $24.95 | 2019 | |
| Eisai INC. | $18.74 | 2019 | |
| Medtronic USA, INC. | $15.62 | 2019 | |
| Mdd US Operations, LLC | $14.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.